Mannatech Inc last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $26.6 million and diluted EPS of $0.53. It usually reports 15–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 15–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
27
|
1
|
0.53
|
|
Apr 15, 2026
15 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
25
-6.2%
|
1
+162.1%
|
0.49
+161.2%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
29
-8.1%
|
2
+686.6%
|
1.01
+694.1%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
32
-2.5%
|
-0
-154.3%
|
-0.17
-1800.0%
|
|
Aug 13, 2024
44 days after quarter end
|
Q2 FY2024
ended Jun 30, 2024
|
28
-14.9%
|
-1
+43.5%
|
-0.33
+44.1%
|
|
May 14, 2024
44 days after quarter end
|
—
ended Mar 31, 2024
|
—
|
—
|
—
|
|
Nov 7, 2023
38 days after quarter end
|
—
ended Sep 30, 2023
|
—
|
—
|
—
|
|
Aug 14, 2023
45 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- MTEX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Flower Mound, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1056358
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.